Novartis Analyst Ratings
Novartis Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | — | Morgan Stanley | Upgrades | Underweight → Equal-Weight | |
| 05/09/2022 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 12/06/2021 | — | Exane BNP Paribas | Downgrades | Outperform → Neutral | |
| 12/03/2021 | — | Bryan Garnier | Downgrades | Buy → Neutral | |
| 09/20/2021 | — | Deutsche Bank | Downgrades | Hold → Sell | |
| 03/10/2021 | — | Argus Research | Downgrades | Buy → Hold | |
| 02/01/2021 | 3.82% | Cowen & Co. | $110 → $105 | Downgrades | Outperform → Market Perform |
| 01/15/2021 | — | Deutsche Bank | Initiates Coverage On | → Buy | |
| 09/01/2020 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 02/25/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/25/2019 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 04/10/2019 | — | Morgan Stanley | Downgrades | Equal-Weight → Underweight | |
| 12/11/2018 | 3.82% | Jefferies | → $105 | Assumes | → Buy |
| 11/26/2018 | -1.13% | Cowen & Co. | → $100 | Upgrades | Market Perform → Outperform |
| 11/19/2018 | — | Goldman Sachs | Upgrades | Neutral → Conviction Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/25/2023 | — | 摩根士丹利 | 升級 | 體重不足 → 重量相等 | |
| 05/09/2022 | — | 沃爾夫研究 | 降級 | 跑贏大盤 → 同行表現 | |
| 12/06/2021 | — | Exane BNP Paribas | 降級 | 跑贏大盤 → 中性 | |
| 2021 年 3 月 12 日 | — | 布萊恩·卡尼爾 | 降級 | 買入 → 中性 | |
| 09/20/2021 | — | 德意志銀行 | 降級 | 持有 → 賣出 | |
| 03/10/2021 | — | 阿格斯研究 | 降級 | 買入 → 持有 | |
| 2021 年 1 月 2 日 | 3.82% | Cowen & Co. | 110 美元 → 105 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 2021 年 1 月 15 日 | — | 德意志銀行 | 啓動覆蓋範圍開啓 | → 購買 | |
| 2020 年 1 月 9 日 | — | 摩根士丹利 | 升級 | 重量相等 → 超重 | |
| 2020 年 2 月 25 日 | — | 古根海姆 | 降級 | 買入 → 中性 | |
| 2019 年 4 月 25 日 | — | 古根海姆 | 升級 | 中性 → 買入 | |
| 2019 年 10 月 4 日 | — | 摩根士丹利 | 降級 | 等重 → 減重 | |
| 12/11/2018 | 3.82% | 傑富瑞 | → 105 美元 | 假設 | → 購買 |
| 11/26/2018 | -1.13% | Cowen & Co. | → 100 美元 | 升級 | 市場表現 → 跑贏大盤 |
| 11/19/2018 | — | 高盛 | 升級 | 中性 → 定罪買入 |
What is the target price for Novartis (NVS)?
諾華（NVS）的目標價格是多少？
The latest price target for Novartis (NYSE: NVS) was reported by Morgan Stanley on September 25, 2023. The analyst firm set a price target for $0.00 expecting NVS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
摩根士丹利於2023年9月25日公佈了諾華（紐約證券交易所代碼：NVS）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計NVS將在12個月內跌至-100.00％（可能下跌-100.00％）。去年有1家分析公司公佈了評級。
What is the most recent analyst rating for Novartis (NVS)?
諾華 (NVS) 的最新分析師評級是多少？
The latest analyst rating for Novartis (NYSE: NVS) was provided by Morgan Stanley, and Novartis upgraded their equal-weight rating.
諾華（紐約證券交易所代碼：NVS）的最新分析師評級由摩根士丹利提供，諾華上調了同權評級。
When is the next analyst rating going to be posted or updated for Novartis (NVS)?
諾華（NVS）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novartis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novartis was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與諾華的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。諾華的最新評級是在2023年9月25日提交的，因此您應該預計下一個評級將在2024年9月25日左右公佈。
Is the Analyst Rating Novartis (NVS) correct?
諾華 (NVS) 的分析師評級是否正確？
While ratings are subjective and will change, the latest Novartis (NVS) rating was a upgraded with a price target of $0.00 to $0.00. The current price Novartis (NVS) is trading at is $101.14, which is out of the analyst's predicted range.
雖然評級是主觀的，並且會發生變化，但最新的諾華（NVS）評級已上調，目標價爲0.00美元，至0.00美元。諾華（NVS）目前的交易價格爲101.14美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。